Bokf Na Has $10.55 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

BOKF NA grew its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 10.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 64,623 shares of the company's stock after buying an additional 6,024 shares during the period. BOKF NA's holdings in Zoetis were worth $10,554,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in ZTS. Atlantic Edge Private Wealth Management LLC grew its stake in shares of Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock worth $28,000 after purchasing an additional 140 shares in the last quarter. Rakuten Securities Inc. grew its position in Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock valued at $28,000 after buying an additional 166 shares in the last quarter. Navigoe LLC acquired a new position in Zoetis during the 4th quarter valued at about $30,000. Murphy & Mullick Capital Management Corp bought a new stake in shares of Zoetis during the 4th quarter worth about $44,000. Finally, Asset Planning Inc acquired a new stake in shares of Zoetis in the 4th quarter worth approximately $58,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently commented on ZTS shares. Barclays raised their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. Stifel Nicolaus dropped their price objective on Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Piper Sandler raised their target price on Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a research note on Thursday, February 27th. StockNews.com upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. Finally, UBS Group reduced their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research report on Wednesday. One analyst has rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $212.13.

Insiders Place Their Bets

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the sale, the director now owns 11,245 shares in the company, valued at $1,868,244.30. This represents a 9.71 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the transaction, the executive vice president now owns 15,781 shares in the company, valued at approximately $2,682,770. This represents a 2.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,862 shares of company stock worth $312,254. 0.18% of the stock is currently owned by company insiders.

Zoetis Trading Down 1.1 %

Shares of ZTS stock traded down $1.73 during trading hours on Friday, reaching $159.96. 4,243,109 shares of the stock traded hands, compared to its average volume of 2,492,973. The business has a fifty day moving average price of $157.27 and a 200 day moving average price of $166.06. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The firm has a market capitalization of $71.37 billion, a PE ratio of 29.24, a PEG ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. During the same quarter in the prior year, the company earned $1.38 earnings per share. The company's revenue for the quarter was up 1.4% on a year-over-year basis. On average, equities research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.